A2T.F ATRYS HEALTH S.A. EO-01

Healthcare Biotechnology Frankfurt Exchange
2.54 EUR
Close of Nov 11, 2026
2.06 3.04
Market cap
EUR 193M
P/E
-
P/B
1.28x
ROE
-66.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is A2T.F undervalued?

Graham number

The Graham number of ATRYS HEALTH S.A. EO-01 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ATRYS HEALTH S.A. EO-01 fundamental analysis

No fundamental analysis for ATRYS HEALTH S.A. EO-01 yet.

ATRYS HEALTH S.A. EO-01 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ATRYS HEALTH S.A. EO-01

Atrys Health, S.A., together with its subsidiaries, provides diagnostic services and medical treatments in Spain, Portugal, and Latin America. It operates through three segments: Diagnosis, Oncology, and Preventive Medicine. The company offers integrated diagnostics services comprising structural and molecular pathology, genetics, and nuclear medicine diagnosis; telediagnosis activities in the fields of radiology and cardiology; oncology treatment services, such as chemother…

Full company profile